A Phase 3, Multinational, Randomized, Placebo-controlled Study of ARRY-371797 (PF07265803) in Patients with Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation
Study of Drug (ARRY-371797) Effects for Adults with Genetic Dilated Cardiomyopathy (DCM)
Sponsor: Pfizer
Enrolling: Male and Female Patients
IRB Number: AAAR8508
U.S. Govt. ID: NCT03439514
Contact: Austin Nguonly: 212-305-1368 / caccresearch@cumc.columbia.edu
Additional Study Information: A study to find out if the experimental drug ARRY-371797 vs. placebo has beneficial effects on ability to walk over a 6-minute period (as measured by the 6-minute walk test) in adults with genetic dilated cardiomyopathy.
This study is closed
Investigator
Farhana Latif, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Do you have a diagnosis of heart failure or dilated cardiomyopathy? Yes No
Do you have an ICD or CRT device implanted? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Austin Nguonly
caccresearch@cumc.columbia.edu
212-305-1368
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE